Company: DMAAR
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001213900-25-076681
Chunk: 2

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 2
---
 Basic net income (loss) per non-redeemable ordinary share
     
    $
    0.07

    $
    0.12

    $
    (0.01
    )
  
    Weighted average non-redeemable ordinary shares outstanding (1)(2)

    10,517,143

    10,424,325

    8,571,429

    Diluted net income (loss) per non-redeemable ordinary share
     
    $
    0.07

    $
    0.12

    $
    (0.01
    )

(1)Includes an aggregate of up to 1,285,714 ordinary shares subject
to surrender and forfeiture if the over-allotment option were not exercised in full by the underwriters (Note 5). In February 2025, the
over-allotment option was exercised by the underwriters and these shares are no longer subject to forfeiture (Note 9).

(2)On November 6, 2024, the Sponsor surrendered and forfeited 12,503,968
ordinary shares to the Company for no consideration, following which the Sponsor held 9,857,143 ordinary shares. All share and per share
data has been retrospectively presented.

The accompanying notes are an integral part of
the unaudited financial statements.

2

DRUGS MADE IN AMERICA ACQUISITION CORP.

STATEMENTS OF CHANGES IN SHAREHOLDERS’
DEFICIT

(UNAUDITED)

FOR THE THREE AND SIX MONTHS ENDED JUNE 30,
2025

    Ordinary Shares  
    Share Subscription  
    Additional Paid-in  
    Accumulated  
    Total Shareholders’ 

    Shares  
    Amount  
    Receivable  
    Capital  
    Deficit  
    Deficit 
  
    Balance — January 1, 2025 
     9,857,143  
    $986  
    $—  
    $34,014  
    $(279,845) 
    $(244,845)

    Sale of 430,000 Private Placement Units 
     430,000  
     43  
     (1,100,000) 
     4,299,957  
     —  
     3,200,000 

    Fair value of representative shares 
     230,000